The big clinical trials in idiopathic pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 5, 2012, Pages 428-432

  Luppi, Fabrizio ^a   Spagnolo, Paolo ^a   Cerri, Stefania ^a   Richeldi, Luca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

bosentan; clinical trials; idiopathic pulmonary fibrosis; pirfenidone

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISONE;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG USE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84864872340     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283567ff9     Document Type: Review

References (22)

1. aghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949-1961
3. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963-967.
4. American Thoracic Society. Idiopathic pul monary ibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-664.
5. Peikert T, Daniels CE, Beebe TJ, et al. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 2008; 102:1342-1348.
6. icheldi L, Costabel U, SelmanM, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079-1087.
7. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-4782.
8. Downey GP. Resolving the scar of pulmonary fibrosis. N Engl J Med 2011; 365:1140-1141
9. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242. (Pubitemid 41697286)
10. Wells AU, Behr J, Costabel U,et al. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J 2012; 39:805-806.
11. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75-81.
12. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903. (Pubitemid 34984638)
13. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:92-99.
14. Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelialmesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol 2007; 37:38-47. (Pubitemid 46999535)
15. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047. (Pubitemid 40616955)
16. oble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
17. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821-829.
18. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377:1727-1729.
19. Spagnolo P, Del Giovane C, Luppi F, et al. Nonsteroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9:CD003134.
20. Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40:362-382. (Pubitemid 351249887)
21. icheldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67:407-411.
22. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512.